Proteomics

Dataset Information

0

SILAC-based proteomic approach to delineate molecular alterations associated with erlotinib resistance in head and neck squamous cell carcinoma

ABSTRACT: Although Epidermal growth factor receptor (EGFR) is overexpressed in 90% of Head and neck squamous cell carcinoma (HNSCC) patients. Clinical trials with EGFR-targeted small molecule inhibitors such as erlotinib have shown a modest activity in recurrent or advanced HNSCC. To investigate the acquired mechanisms of erlotinib resistance we employed SILAC-based total proteomic analysis of an isogenic pair of erlotinib sensitive (SCC-S) and resistant (SCC-R) HNSCC cell line. This resulted in the identification of 5,427 proteins of which 532 proteins were overexpressed and 527 proteins were downregulated in SCC-R cells as compared to SCC-S cells (≥2 fold). Several proteins known to mediate erlotinib resistance in HNSCC and lung cancer were found to be dysregulated. Bioinformatics analysis of differentially expressed proteins showed enrichment of proteins involved in focal adhesion kinase (FAK) pathway downstream of EGFR. We identified CUB-domain containing protein 1 (CDCP1) and integrin β1 as upstream regulators of FAK signalling pathway to be overexpressed. We further demonstrated that CDCP1 and FAK can be targeted in combination as an alternative to erlotinib in HNSCC.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Oral Epithelium

SUBMITTER: Harsha Gowda  

LAB HEAD: Harsha Gowda

PROVIDER: PXD007768 | Pride | 2019-12-18

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a therapeutic challenge. In this study, we employed an integrated multi-omics approach to delineate mechanisms associated with acquired resistance to erlotinib by carrying out whole exome sequencing, q  ...[more]

Similar Datasets

Proteomics Genetic aberrations in MAP kinase pathway play an important role in erlotinib resistance in head and neck cancer
2019-12-18 | PXD007785 | Pride
Proteomics SILAC-based quantitative tyrosine phosphoproteomic profiling identifies alternative therapeutic targets to erlotinib in head and neck squamous cell carcinoma
2022-10-13 | PXD007769 | Pride
Transcriptomics Genome-wide gene expression analysis of EGFR inhibitor erlotinib-resistant and -sensitive head and neck squamous cell carcinoma cell lines Cal-27, SCC-25, FaDu, and SQ20B
2014-10-07 | GSE62061 | GEO
Transcriptomics Genome-wide analysis of EGFR inhibitor erlotinib treatment in Head and neck, squamous cell carcinoma's FADU, SQ20B and Cal 27
2014-04-08 | E-GEOD-45891 | biostudies-arrayexpress
Transcriptomics Charaterization of genetic alterations and gene expression signatures found in erlotinib-resistant and erlotinib/crizotinib dual-resistant HCC827 subpopulations
2014-10-07 | E-GEOD-62118 | biostudies-arrayexpress
Transcriptomics Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib
2013-08-10 | E-GEOD-49135 | biostudies-arrayexpress
Proteomics SILAC proteomics analysis to discover effect sensors of EGFR inhibition
2018-10-18 | PXD005985 | Pride
Transcriptomics Microarray study to understand acquired resistance to EGFR-targeted therapy in lung cancer
2012-05-29 | E-GEOD-38310 | biostudies-arrayexpress
Transcriptomics Expression data from EGFR WT or EGFR mutant NSCLC with or without erlotinib
2014-05-16 | E-GEOD-57156 | biostudies-arrayexpress
Proteomics Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-HCC1954]
2012-10-22 | E-GEOD-36324 | biostudies-arrayexpress